Article in Journal of immunology (Baltimore, Md. : 1950), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors at 6 institutions in 2 countries.
Guilherme A MeloDepartamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0001-5144-5139
Tianhao XuCenter for Cancer Cell Biology, Immunology, and Infection, Discipline of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL.ORCID 0000-0003-2935-6353
Carolina CalôbaDepartamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-4723-2127
Alexander SchutteCenter for Cancer Cell Biology, Immunology, and Infection, Discipline of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL.
Thaís O PassosDepartamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Moisés A N NetoDepartamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Gabrielle BrumDepartamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0009-0009-6499-6277
Bárbara Oliveira-VieiraPrograma de Imunologia e Biologia Tumoral, Instituto Nacional do Câncer, Rio de Janeiro, RJ, Brazil.
Luiza HigaDepartamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-2622-534X
Fábio L L MonteiroDepartamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-9107-6865
Luiz BerbertCoordenação de Atividade com Modelos Biológicos Experimentais, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-0541-4002
André N A GonçalvesDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil.ORCID 0000-0001-5264-8368
Amilcar TanuriDepartamento de Genética, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-0570-750X
João P B ViolaPrograma de Imunologia e Biologia Tumoral, Instituto Nacional do Câncer, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-0698-3146
Miriam B F WerneckInstituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0003-1287-8526
Helder I NakayaHospital Israelita Albert Einstein, Sao Paulo, SP, Brazil.
Matthew E PipkinDepartment of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, FL.ORCID 0000-0002-9688-0190
Gustavo J MartinezCenter for Cancer Cell Biology, Immunology, and Infection, Discipline of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL.
Renata M PereiraDepartamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.ORCID 0000-0002-7719-8356
Universidade Federal do Rio de Janeiro · BRRosalind Franklin University of Medicine and Science · USInstituto Nacional de Câncer - INCA · BRHospital Israelita Albert Einstein · BRScripps Research Institute · USUniversidade de São Paulo · BR
Funding
Transcription factor regulation of CD4 and CD8 T cell effector and memory differentiation and functionP01AI145815 · NIAID · UNIVERSITY OF FLORIDA · PI PIPKIN, MATTHEW EUGENE · 2020 to 2024
$11.0M
TF regulation of CD8 and CD4 T cell memory in both systemic and dermal infectionU19AI109976 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI PETERS, BJOERN · 2014 to 2018
CTL differentiation is controlled by the crosstalk of various transcription factors and epigenetic modulators. Uncovering this process is fundamental to improving immunotherapy and designing novel therapeutic approaches. In this study, we show that polycomb repressive complex 1 subunit chromobox (Cbx)4 favors effector CTL differentiation in a murine model. Cbx4 deficiency in CTLs induced a transcriptional signature of memory cells and increased the memory CTL population during acute viral infection. It has previously been shown that besides binding to H3K27me3 through its chromodomain, Cbx4 functions as a small ubiquitin-like modifier (SUMO) E3 ligase in a SUMO-interacting motifs (SIM)-dependent way. Overexpression of Cbx4 mutants in distinct domains showed that this protein regulates CTL differentiation primarily in an SIM-dependent way and partially through its chromodomain. Our data suggest a novel role of a polycomb group protein Cbx4 controlling CTL differentiation and indicated SUMOylation as a key molecular mechanism connected to chromatin modification in this process.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cutting Edge: Polycomb Repressive Complex 1 Subunit Cbx4 Positively Regulates Effector Responses in CD8 T Cells. · full record | OpenQuestion